MA37475A1 - Biomarqueurs pour thérapie par inhibiteur de iap - Google Patents

Biomarqueurs pour thérapie par inhibiteur de iap

Info

Publication number
MA37475A1
MA37475A1 MA37475A MA37475A MA37475A1 MA 37475 A1 MA37475 A1 MA 37475A1 MA 37475 A MA37475 A MA 37475A MA 37475 A MA37475 A MA 37475A MA 37475 A1 MA37475 A1 MA 37475A1
Authority
MA
Morocco
Prior art keywords
biomarkers
iap inhibitor
inhibitor therapy
iap
therapy
Prior art date
Application number
MA37475A
Other languages
English (en)
Inventor
John Scott Cameron
Caroline Emery
Dale Porter
Douglas Robinson
Kavitha Venkatesan
Li Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37475A1 publication Critical patent/MA37475A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

La présente invention concerne un procédé de sélection d'un sujet ayant un cancer pour traitement avec un inhibiteur de iap.
MA37475A 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap MA37475A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Publications (1)

Publication Number Publication Date
MA37475A1 true MA37475A1 (fr) 2016-05-31

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37475A MA37475A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Country Status (20)

Country Link
US (1) US9353419B2 (fr)
EP (1) EP2844764B1 (fr)
JP (1) JP6513019B2 (fr)
KR (1) KR20150011822A (fr)
CN (1) CN104284988A (fr)
AU (1) AU2013256182A1 (fr)
BR (1) BR112014027413A2 (fr)
CA (1) CA2871995A1 (fr)
CL (1) CL2014002976A1 (fr)
ES (1) ES2593046T3 (fr)
HK (1) HK1202589A1 (fr)
IL (1) IL235315A0 (fr)
MA (1) MA37475A1 (fr)
MX (1) MX2014013429A (fr)
PH (1) PH12014502461A1 (fr)
RU (1) RU2014148779A (fr)
SG (1) SG11201406837TA (fr)
TN (1) TN2014000443A1 (fr)
TW (1) TW201347760A (fr)
WO (1) WO2013166344A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
CA2970525A1 (fr) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibiteurs de necrose cellulaire et procedes associes
KR20200081417A (ko) * 2017-11-01 2020-07-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 아폽토시스 억제제 단백질을 표적화하는 신규 작용제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
CA2553871A1 (fr) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Peptidomimetiques de smac et utilisations associees
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
RU2425838C2 (ru) 2004-04-07 2011-08-10 Новартис Аг Ингибиторы iap
PL1778718T3 (pl) 2004-07-02 2015-03-31 Genentech Inc Inhibitory IAP
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
NZ589670A (en) 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
EP1960551A2 (fr) * 2005-12-01 2008-08-27 Medical Prognosis Institute Méthodes et appareils pour identifier des biomarqueurs de réponse à un traitement et leur utilisation pour prédire l'efficacité d un traitement
CA2665838A1 (fr) * 2006-10-19 2008-05-15 Novartis Ag Composes organiques
CN101529254A (zh) * 2006-10-19 2009-09-09 诺瓦提斯公司 有机化合物
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
EP2382465A1 (fr) * 2009-01-29 2011-11-02 Otto-von-Guericke-Universität Magdeburg Procédé de détermination de sensibilité de cellules humaines ou animales non humaines à un antagoniste de iap
JP2012517238A (ja) * 2009-02-11 2012-08-02 カリス エムピーアイ インコーポレイテッド 腫瘍の分子プロファイリング法
EP2478358A1 (fr) * 2009-09-18 2012-07-25 Novartis AG Biomarqueurs associés aux composés inhibiteurs des iap
CN101956014B (zh) 2010-09-30 2014-05-28 中山大学 一种用于鼻咽癌早期诊断的外周血7个基因标志物的检测试剂盒

Also Published As

Publication number Publication date
AU2013256182A1 (en) 2014-11-13
BR112014027413A2 (pt) 2017-06-27
EP2844764A1 (fr) 2015-03-11
CA2871995A1 (fr) 2013-11-07
EP2844764B1 (fr) 2016-06-22
US9353419B2 (en) 2016-05-31
CL2014002976A1 (es) 2015-02-13
HK1202589A1 (zh) 2015-10-02
RU2014148779A (ru) 2016-06-27
SG11201406837TA (en) 2014-11-27
CN104284988A (zh) 2015-01-14
MX2014013429A (es) 2014-12-08
US20150105434A1 (en) 2015-04-16
WO2013166344A1 (fr) 2013-11-07
PH12014502461A1 (en) 2014-12-22
JP6513019B2 (ja) 2019-05-15
JP2015523056A (ja) 2015-08-13
ES2593046T3 (es) 2016-12-05
IL235315A0 (en) 2014-12-31
TN2014000443A1 (en) 2016-03-30
KR20150011822A (ko) 2015-02-02
TW201347760A (zh) 2013-12-01

Similar Documents

Publication Publication Date Title
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
BR112013024211A2 (pt) tratamento de tumores sólidos
MY182386A (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
EA201400178A1 (ru) Лечение рака молочной железы
UA110813C2 (uk) Лікування ліподистрофії
BR112013025755A2 (pt) aparelho de guincho
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
BR112013027726A2 (pt) instalação de poço submarino e método associado
EP3394032A4 (fr) Composés et méthodes de traitement, de dépistage, et d'identification de composés destinés à traiter les maladies provoquées par des parasites apicomplexes
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
EP2723866A4 (fr) Procédés de pronostic et/ou de diagnostic d'une maladie neurodégénérative, procédés d'identification de composés candidats et composés pour le traitement d'une maladie neurodégénérative
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
BR102013026779A8 (pt) ferramenta de esmerilhar
EA201492104A1 (ru) Ингибитор jak1/2
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
NZ712023A (en) Caix stratification based cancer treatment
GB2510539A (en) Biomarkers of cancer
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia